The ACTA1 gene myopathy with fiber-type disproportion genetic test is a specialized diagnostic tool aimed at identifying mutations in the ACTA1 gene, which are known to cause a form of congenital myopathy characterized by muscle weakness and fiber-type disproportion. This condition, often diagnosed in infancy or early childhood, manifests through a range of symptoms including hypotonia, delayed motor milestones, and respiratory issues, among others. The ACTA1 gene plays a crucial role in encoding the skeletal muscle actin, a key component of the muscle contractile system. Mutations in this gene can disrupt muscle function, leading to the clinical features observed in affected individuals.
The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to identify any genetic alterations in the ACTA1 gene. It is a critical step for confirming the diagnosis, understanding the disease progression, and guiding treatment options. Furthermore, it can provide essential information for family planning and genetic counseling for families affected by this condition.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test ensures high accuracy and reliability. The cost of the ACTA1 gene myopathy with fiber-type disproportion genetic test is set at 4400 AED, reflecting the sophisticated technology and expertise required to perform this advanced genetic analysis. Opting for this test at DNA Labs UAE offers patients and their families the assurance of comprehensive support, from initial consultation through to result interpretation and beyond, in managing this complex genetic condition.
The SELENON Gene Myopathy with Fiber-Type Disproportion Genetic Test is a specialized diagnostic examination available at DNA Labs UAE, designed to detect mutations in the SELENON gene, which are associated with a rare form of myopathy known as SELENON-related myopathy or SEPN1-related myopathy. This condition is characterized by muscle weakness and fiber-type disproportion, a pathological finding where there is a significant difference in size between type 1 and type 2 muscle fibers without any other significant abnormalities. The test is crucial for the accurate diagnosis of the condition, enabling healthcare providers to tailor management and intervention strategies effectively for affected individuals.
Priced at 3200 AED, the test involves analyzing the patient's DNA to identify any genetic alterations in the SELENON gene that might lead to the development of the disease. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test is a powerful tool for families and individuals seeking answers to unexplained muscle weakness and related symptoms, potentially guiding them towards appropriate treatment options and genetic counseling.
The "MEGF10 Gene Myopathy Areflexia Respiratory Distress and Dysphagia Early-Onset Genetic Test" is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the MEGF10 gene, which are associated with a rare genetic disorder. This condition is characterized by a range of symptoms including muscle weakness (myopathy), absence of reflexes (areflexia), difficulty breathing (respiratory distress), and problems with swallowing (dysphagia) that manifest early in life. The test, priced at 4400 AED, involves analyzing the patient's DNA to identify any genetic alterations in the MEGF10 gene that could lead to the disorder. By providing a precise genetic diagnosis, this test enables targeted management and treatment strategies, offering hope and support to affected individuals and their families. DNA Labs UAE employs state-of-the-art technology and expertise to ensure accurate and reliable test results.
The COL6A6 gene myopathy refers to a group of disorders caused by mutations in the COL6A6 gene. This gene is crucial for encoding a component of type VI collagen, which plays a significant role in the structure and function of muscle tissue and other connective tissues. Mutations in the COL6A6 gene can lead to muscle weakness, joint abnormalities, and a variety of other symptoms, depending on the severity and type of mutation.
To diagnose conditions related to the COL6A6 gene, genetic testing is available. One such test is offered by DNA Labs UAE, a leading facility in genetic diagnostics. The COL6A6 related genetic test is a comprehensive analysis designed to detect mutations in the COL6A6 gene that could lead to myopathy and related disorders. This test is critical for confirming a diagnosis, understanding the risk of passing the mutation to offspring, and guiding treatment options.
The cost of the COL6A6 related genetic test at DNA Labs UAE is 4400 AED. This investment covers the collection of a DNA sample, usually through a blood draw or a cheek swab, and its subsequent analysis in the laboratory. The test results can provide invaluable information for affected individuals and their families, including the potential for personalized treatment plans and management strategies to improve quality of life.
The CRYAB gene myopathy, also known as desmin-related myopathy, is a rare genetic disorder characterized by muscle weakness and abnormalities. This condition is associated with mutations in the CRYAB gene, which plays a crucial role in the stability and function of muscle cells. The CRYAB gene encodes for alpha-crystallin B, a small heat shock protein that is significant in preventing the aggregation of misfolded proteins, thus ensuring the proper functioning of muscle fibers.
To diagnose this condition, a genetic test can be performed to identify mutations in the CRYAB gene. DNA Labs UAE offers this specialized test, providing a crucial tool for the accurate diagnosis of CRYAB gene myopathy. The test involves analyzing the patient's DNA to look for specific mutations in the CRYAB gene that are known to cause the disorder. This genetic test is pivotal for families with a history of the condition, as it can help in early diagnosis, management, and understanding the risk of passing the mutation to future generations.
The cost of the genetic test for CRYAB gene myopathy at DNA Labs UAE is 4400 AED. This investment is crucial for affected individuals and their families, as it provides essential information for the management of the condition, potential treatment options, and genetic counseling. Early diagnosis through this genetic test can significantly impact the quality of life of individuals with CRYAB gene myopathy by enabling timely interventions and personalized care plans.
The MYH7 gene myopathy distal type 1 genetic test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the MYH7 gene that are associated with distal myopathy type 1, a rare inherited muscle disorder. This condition is characterized by weakness and atrophy of the distal muscles, primarily affecting the lower legs and hands, and can lead to significant impairment in mobility and hand function.
Distal myopathy type 1 is caused by mutations in the MYH7 gene, which encodes the beta-myosin heavy chain protein, a crucial component of the contractile system in skeletal and cardiac muscles. The genetic test involves analyzing the patient's DNA, extracted from a blood sample, to search for specific mutations in the MYH7 gene that are known to cause the disorder.
The test is priced at 4400 AED and is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high accuracy and reliability of the results. The test is critical for individuals with a family history of distal myopathy type 1 or those exhibiting symptoms, as a positive result can confirm the diagnosis and facilitate early intervention and management strategies. Additionally, the test can provide valuable information for family planning and genetic counseling for affected individuals and their families.
The FLNC Gene Myopathy Distal Type 4 Genetic Test is a specialized diagnostic tool designed to identify mutations in the FLNC gene, which are associated with Distal Myopathy Type 4. This condition is a rare genetic disorder characterized by muscle weakness and atrophy, primarily affecting the lower limbs and, in some cases, progressing to involve upper limbs and other muscle groups. The FLNC gene plays a crucial role in muscle function and stability, and mutations in this gene can disrupt normal muscle architecture, leading to the symptoms observed in affected individuals.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, this test involves analyzing the patient's DNA to detect abnormalities in the FLNC gene that could indicate the presence of Distal Myopathy Type 4. The process is meticulous, ensuring high accuracy and reliability in the results.
The cost of the FLNC Gene Myopathy Distal Type 4 Genetic Test is set at 4400 AED. While the price may seem significant, it reflects the advanced technology and expertise required to perform such specialized genetic testing. For patients and families affected by this condition, the test offers invaluable information for confirming the diagnosis, understanding the risk of passing the condition to offspring, and making informed decisions about management and treatment options.
DNA Labs UAE is known for its commitment to providing comprehensive and confidential genetic testing services, making it a trusted choice for individuals seeking answers to complex genetic questions.
The "DYSF Gene Myopathy Distal with Anterior Tibial Onset Genetic Test" is a specialized diagnostic assessment designed to identify mutations in the DYSF gene, which are implicated in a rare form of muscular dystrophy known as Dysferlinopathy. This condition is characterized by muscle weakness and atrophy, initially affecting the anterior tibial muscles in the legs, and can progressively involve other muscle groups. The test is crucial for confirming the diagnosis, understanding the disease progression, and guiding treatment options.
Performed at DNA Labs UAE, the test involves analyzing the patient's DNA to detect specific genetic alterations in the DYSF gene. The process requires a sample of the patient's blood or saliva, from which DNA is extracted and examined for the presence of mutations associated with the condition.
The cost of the test is set at 4400 AED, reflecting the comprehensive nature of the genetic analysis and the specialized expertise required to interpret the results. By providing a definitive diagnosis, this test plays a vital role in the management of patients with symptoms suggestive of Dysferlinopathy, enabling targeted interventions and genetic counseling for affected individuals and their families.
The CAV3 Gene Myopathy Distal Tateyama Type Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, designed to identify mutations in the CAV3 gene, which are linked to the development of Distal Tateyama Type Myopathy. This condition is a rare form of muscle disorder that affects the distal muscles, leading to weakness and atrophy primarily in the limbs. The CAV3 gene plays a crucial role in encoding caveolin-3, a protein vital for the normal functioning of muscle cells.
The test is conducted through a detailed analysis of the patient's DNA to pinpoint any genetic abnormalities present in the CAV3 gene. It is a critical tool for confirming the diagnosis of Distal Tateyama Type Myopathy, allowing for a better understanding of the condition and enabling personalized treatment plans. The genetic test is priced at 4400 AED and is available at DNA Labs UAE, a leading facility renowned for its advanced genetic testing services and commitment to providing accurate and comprehensive diagnostic solutions.
The "TTN Gene Myopathy Early-Onset with Fatal Cardiomyopathy Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the TTN gene. These mutations are associated with early-onset myopathy, a condition characterized by muscle weakness and wasting, which can lead to severe, often fatal, cardiomyopathy - a disease of the heart muscle that makes it harder for the heart to pump blood to the rest of the body.
This genetic test is crucial for individuals who exhibit symptoms of myopathy or have a family history of cardiomyopathy, as early detection can significantly influence management and treatment options. The test involves analyzing the patient's DNA to look for specific genetic alterations in the TTN gene, which is known to play a vital role in muscle function and structure.
Priced at 4400 AED, the test is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring accuracy and reliability of the results. By opting for this test, patients and their families can gain valuable insights into their genetic predisposition to these conditions, enabling them to make informed decisions regarding their health and future.
